To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

NCT00761540 · Completed

Last updated 2026-05-28

This clinical trial tests how liraglutide, a diabetes medication, affects blood sugar and insulin levels in people with diabetes and healthy volunteers after 21 days of daily injections.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 37 people

Who can join Ages 18–45 · male only Healthy volunteers accepted.

Timeline Started 2008-10 · est. completion 2008-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT00761540 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynamics) after 21 days of daily subcutaneous injections (injected under the skin) of liraglutide or placebo. In addition, the safety and tolerability of liraglutide will be observed.

Treatments tested

liraglutide Drug

Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
placebo Drug

Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
liraglutide Drug

Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
placebo Drug

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
liraglutide Drug

Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
placebo Drug

Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)

Main thing measured	AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00761540 ↗